2025-07-13 - Analysis Report
Okay, here's the analysis of Eli Lilly and Co (LLY), formatted as requested.

## Eli Lilly and Co (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** LLY
*   **Cumulative Return (LLY):** 256.89%
*   **Cumulative Return (VOO):** 95.46%
*   **Absolute Divergence:** 161.43% (LLY outperformed VOO by this amount)
*   **Divergence Range:** Max: 311.6, Min: -27.3
*   **Relative Divergence:** 55.2 (This indicates that LLY's outperformance is in the upper-middle range of its historical divergence from the S&P 500).

**Analysis of Provided Table:**

| Year       | CAGR    | MDD    | Alpha    | Beta   | Cap(B) |
|------------|---------|--------|----------|--------|--------|
| 2015-2017  | 10.0%   | 56.3%  | -19.0%   | 0.0    | 75.8   |
| 2016-2018  | 39.0%   | 58.6%  | 21.0%    | -0.1   | 103.9  |
| 2017-2019  | 50.0%   | 58.6%  | 20.0%    | 0.3    | 118.0  |
| 2018-2020  | 52.0%   | 58.6%  | 33.0%    | 0.1    | 151.6  |
| 2019-2021  | 106.0%  | 60.6%  | 57.0%    | 0.2    | 248.0  |
| 2020-2022  | 98.0%   | 64.8%  | 96.0%    | 0.2    | 328.4  |
| 2021-2023  | 133.0%  | 64.8%  | 115.0%   | 0.3    | 523.3  |
| 2022-2024  | 150.0%  | 72.2%  | 124.0%   | 0.2    | 693.0  |
| 2023-2025  | 110.0%  | 76.8%  | 62.0%    | 0.2    | 711.9  |

*   **CAGR:** Compound Annual Growth Rate is consistently high, demonstrating strong growth. The most recent period (2023-2025) shows a CAGR of 110%, still robust.
*   **MDD:** Maximum Drawdown is significant, indicating potential volatility and risk.  The MDD has been increasing in the later periods.
*   **Alpha:** Positive and generally increasing Alpha values indicate that LLY has consistently outperformed the market (S&P 500) on a risk-adjusted basis.  Very strong Alpha in recent years.
*   **Beta:** Beta values are relatively low, suggesting LLY's price movements are not highly correlated with the overall market.
*   **Cap(B):**  Market capitalization has grown substantially over time, reflecting the company's success and growth.

### 2. Recent Stock Price Movements

*   **Current Price:** 793.01
*   **Previous Close:** 790.65
*   **Change:** 0.3%
*   **5-day Moving Average:** 784.22
*   **20-day Moving Average:** 786.42
*   **60-day Moving Average:** 781.26

**Analysis:**

*   The current price is slightly above the previous close, indicating a small increase.
*   The price is above all three moving averages (5, 20, and 60-day), which can be interpreted as a short to medium-term upward trend. The 5-day moving average is also above the 20-day moving average, suggesting bullish momentum.

### 3. Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3294 (Low Risk)
*   **RSI:** 66.03 (Approaching overbought territory, but not yet extreme)
*   **PPO:** 0.0468 (Positive, indicating bullish momentum)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.33)
*   **Delta_Previous_Relative_Divergence:** 1.0 (+): Short-term increase
*   **Expected Return (%):** 132.6% (Long-term expected outperformance vs. S&P 500)

**Analysis:**

*   The low MRI suggests relatively low market risk.
*   The RSI is approaching overbought levels, suggesting the stock may be due for a minor pullback.
*   The positive PPO supports the upward trend.
*   The Hybrid Signal suggests a strong buy recommendation, with nearly all available cash to be used for purchasing the stock.
*   The positive change in relative divergence indicates recent positive price movement compared to the S&P 500.
*   A significant expected return of 132.6% indicates that LLY is projected to significantly outperform the S&P 500 over the long term if invested at the current price.
*   **Price change Alert:** The price shows a slight increase over the previous close, with a change of 0.3%. This suggests a normal market fluctuation.

### 4. Recent News & Significant Events

*   **2025-07-13:** Major business developments, regulatory changes, or market events impacting Eli Lilly.
*   **2025-07-09:** Analysts discussing LLY's recent performance and outlook.
*   **2025-07-11:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-07-10:** Market experts highlighting both risks and opportunities for LLY.

**Analysis:**

*   Recent news indicates significant activity surrounding LLY, including potential regulatory changes, analyst discussions, and market volatility. Investors should monitor these developments closely.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2025-05-01 | 2.49 | 8.77 B$ |

**Analysis:**

*   The Earnings per Share (EPS) has fluctuated.  The highest EPS was on 2024-08-08 with 3.29.
*   Revenues show an increase over the last several quarters.  Revenue grew significantly from early 2024 to early 2025.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |
| 2024-06-30   | $11.30B   | 80.80%        |
| 2024-03-31   | $8.77B    | 80.91%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE        |
|--------------|------------|------------|
| 2025-03-31   | $15.76B   | 17.50%     |
| 2024-12-31   | $14.19B   | 31.07%     |
| 2024-09-30   | $14.24B   | 6.81%      |
| 2024-06-30   | $13.56B   | 21.88%     |
| 2024-03-31   | $12.81B   | 17.51%     |

**Analysis:**

*   **Revenue:** Revenue has generally increased over the past five quarters, indicating strong sales growth.
*   **Profit Margin:** The profit margin is consistently high, indicating efficient cost management and strong pricing power.
*   **Equity:** Equity has increased over the past five quarters, reflecting retained earnings and increased asset value.
*   **ROE:** Return on Equity is volatile but generally strong, demonstrating the company's ability to generate profits from shareholder investments.

### 7. Overall Summary

Eli Lilly and Co (LLY) demonstrates robust growth and strong financial performance. It has significantly outperformed the S&P 500. Recent positive trends, including increasing revenue, high profit margins, and a low Market Risk Indicator, point to a promising outlook. However, investors should be aware of the stock's volatility, as indicated by the Maximum Drawdown and recent news events. The RSI is approaching overbought territory, suggesting a potential minor pullback. The long-term expected return is very high. Given the "Hybrid Signal" strong buy recommendation, the stock appears to be a good long-term investment. The increasing revenue, profit margin, equity, and strong ROE further support this conclusion. Continued monitoring of company news and broader market conditions is recommended.
